YZY Biopharma-B (02496.HK): First patient dosed in Phase I clinical trial of Y225 for hemophilia A

Zhitong Finance APP news, YZY Biopharma-B (02496.HK) announced that the first patient has been dosed in the Phase I clinical study in China of the company's investigational emicizumab biosimilar Y225. This Phase I clinical trial is a randomized, double-blind, single-dose, parallel-comparison study designed to evaluate the bioequivalence of Y225 and the reference product Hemlibra (emicizumab injection) in healthy male subjects, providing a basis for the subsequent clinical development of Y225. This marks the project's entry into the human clinical research stage.